The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs
Open accessAbstract
Background —The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction. We compared the coronary vasoconstrictor potential of a number of current and prospective antimigraine drugs (ergotamine, dihydroergotamine, methysergide and its metabolite methylergometrine, sumatriptan, naratriptan, zolmitriptan, rizatriptan, avitriptan). Methods and Results —Concentration-response curves to the antimigraine drugs were constructed in human isolated coronary artery segments to obtain the maximum contractile response (E max ) and the concentration eliciting 50% of E max (EC 50 ). The EC 50 values were related to maximum plasma concentrations (C max ) reported in patients, obtaining C max /EC 50 ratios as an index of coronary vasoconstriction occurring in the clinical setting. Furthermore, we studied the duration of contractile responses after washout of the acutely acting antimigraine drugs to assess their disappearance from the receptor biophase. Compared with sumatriptan, all drugs were more potent (lower EC 50 values) in contracting the coronary artery but had similar efficacies (E max <25% of K + -induced contraction). The C max of avitriptan was 7- to 11-fold higher than its EC 50 value, whereas those of the other drugs were <40% of their respective EC 50 values. The contractile responses to ergotamine and dihydroergotamine persisted even after repeated washings, but those to the other drugs declined rapidly after washing. Conclusions —All current and prospective antimigraine drugs contract the human coronary artery in vitro, but in view of low efficacy, these drugs are unlikely to cause myocardial ischemia at therapeutic plasma concentrations in healthy subjects. In patients with coronary artery disease, however, these drugs must remain contraindicated. The sustained contraction by ergotamine and dihydroergotamine seems to be an important disadvantage compared with sumatriptan-like drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Golino, P., Piscione, F., Willerson, J. T., Cappelli-Bigazzi, M., Focaccio, A., Villari, B., Indolfi, C., Russolillo, E., Condorelli, M., & Chiariello, M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103073241001 · Cited by 426
Plosker, G. L., & McTavish, D. (1994) · Drugs · doi:10.2165/00003495-199447040-00006 · Cited by 179
Connor, H., Feniuk, W., Beattie, D. T., North, P., Oxford, A., Saynor, D. A., & Humphrey, P. P. A. (1997) · Cephalalgia · doi:10.1046/j.1468-2982.1997.1703145.x · Cited by 123
Endothelial nitric oxide and cardiovascular disease
Wennmalm, A. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01081.x · Cited by 107
Single dose pharmacokinetics of sumatriptan in healthy volunteers
Lacey, L. F., Hussey, E. K., & Fowler, P. A. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00193709 · Cited by 102
Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache
Perrin, V. L. (1985) · Clinical Pharmacokinetics · doi:10.2165/00003088-198510040-00004 · Cited by 79
Sumatriptan Clinical Pharmacokinetics
SCOTT, A. K. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427050-00002 · Cited by 76
Pharmacokinetics of methysergide and its metabolite methylergometrine in man
Bredberg, U., Eyjolfsdottir, G. S., Paalzow, L., et al. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00614199 · Cited by 59
Seaber, E. J., ON, N., Phillips, S. E., Churchus, R., Posner, J., & Rolan, P. E. (1996) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1996.tb00172.x · Cited by 57
McFadden, E., Bauters, C., Lablanche, J. M., Leroy, F., Clarke, J. G., Henry, M., Schandrin, C., DAVIES, G. J., Maseri, A., & Bertrand, M. E. (1992) · Circulation · doi:10.1161/01.cir.86.1.187 · Cited by 51
Cited by
Migraine — Current Understanding and Treatment
Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmra010917 · Cited by 1,918
Self-citation5-Hydroxytryptamine receptors in the human cardiovascular system
Kaumann, A. J., & Levy, F. O. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.004 · Cited by 309
Orr, S. L., Aubé, M., Becker, W. J., Davenport, W. J., Dilli, E., Dodick, D., Giammarco, R., Gladstone, J., Leroux, E., Pim, H., et al. (2015) · Cephalalgia · doi:10.1177/0333102414535997 · Cited by 146
Migraine Preventive Medication Reduces Resource Utilization
Silberstein, S. D., Winner, P. K., & Chmiel, J. J. (2003) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2003.03040.x · Cited by 116
Metadata
- Authors
- MaassenVanDenBrink, A., Reekers, M., Bax, W. A., Ferrari, M. D., & Saxena, P. R.
- Venue
- Circulation
- Published
- 1998-07-07
- Volume
- 98
- Issue
- 1
- Pages
- 25-30
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2036354453
- Cited by
- 323
- References
- 13
- FWCI
- 21.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs. https://app.cochat.ai/papers/10.1161/01.cir.98.1.25
- The paper
- MaassenVanDenBrink, A., Reekers, M., Bax, W. A., Ferrari, M. D., & Saxena, P. R. (1998). Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs. Circulation. https://doi.org/10.1161/01.cir.98.1.25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.